Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- CheckyesterdayChange DetectedNo longer looking for participants is now shown on the page, indicating the study has closed enrollment. This update communicates that eligibility and enrollment are no longer active for this trial.SummaryDifference0.4%

- Check8 days agoChange DetectedThe page shows a new revision tag (v3.5.5) replacing the previous v3.5.4, indicating a minor version update to the page's version.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page shows a new Revision: v3.5.4 tag, representing a small software update to the ClinicalTrials.gov page. This change does not modify the study content or documents.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page’s release/version indicator was incremented from “v3.5.2” to “v3.5.3,” reflecting a minor site revision rather than a change to the study record.SummaryDifference0.1%

- Check57 days agoChange DetectedSite revision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check86 days agoChange DetectedThe revision history is updated to include v3.5.0 as the latest revision and removes v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.